510(k) Report

510(k) · Cleared

Cleared

HeRO Graft

K213845510(k) TraditionalCleared Aug 15, 2022249-day reviewClass II21 CFR 870.3450

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Merit Medical Systems, Inc. · DSY Prosthesis, Vascular Graft, Of 6mm And Greater Diameter

Cleared on Aug 15, 2022 as substantially equivalent to K203724 (Merit Medical Systems, Inc., 2021) after a 249-day review. Its family tree reaches back 11 generations to 1979.

Decided
Aug 15, 2022
Review
249 days
Class
Class II
Product code
DSY
Recalls
None
Predicates
1

Its longest line of descent runs back 11 generations to K791810 (1979). 23 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 11 generations backK791810 Vascular Graft Prost. of Expanded PtfeImpra, Inc. · 1979
  2. 7 generations between
  3. 3 generations backK124039 Hero GraftHemoshpere, Inc., A Cryolife Company · 2013
  4. 2 generations backK172637 HeRO GraftMerit Medical Systems, Inc. · 2017
  5. 1 generation backK203724 HeRO Graft, HeRO AdapterMerit Medical Systems, Inc. · 2021
  6. This deviceK213845 HeRO GraftMerit Medical Systems, Inc. · 2022
Show all 11 generations
  1. Root · 11 generations backK791810 Vascular Graft Prost. of Expanded PtfeImpra, Inc. · 1979
  2. 10 generations backK955460 Meadox Medicals, Inc., Expanded & Externally Supported Expanded Ptfe…Meadox Medicals, Div. Boston Scientific Corp. · 1996
  3. 9 generations backK962433 Meadox Exxcel Eptfe Vascular GraftMeadox Medicals, Div. Boston Scientific Corp. · 1997
  4. 8 generations backK052964 Exxcel and Exxcel Soft Eptfe Vascular Grafts, Microvel Double Velour…Boston Scientific Corp · 2006 · Recalled
  5. 7 generations backK071778 Hero Vascular Access DeviceGraftcath, Inc. · 2008
  6. 6 generations backK091491 Hero Vascular Access DeviceHemosphere, Inc. · 2009
  7. 5 generations backK120006 Hero GraftHemosphere, Inc. · 2012
  8. 4 generations backK121532 Hero GraftHemosphere, Inc. · 2012
  9. 3 generations backK124039 Hero GraftHemoshpere, Inc., A Cryolife Company · 2013
  10. 2 generations backK172637 HeRO GraftMerit Medical Systems, Inc. · 2017
  11. 1 generation backK203724 HeRO Graft, HeRO AdapterMerit Medical Systems, Inc. · 2021
  12. This deviceK213845 HeRO GraftMerit Medical Systems, Inc. · 2022
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−11K791810Vascular Graft Prost. of Expanded PtfeImpra, Inc.1979—
−10K955460Meadox Medicals, Inc., Expanded & Externally Supported Expanded Ptfe Vascular…Meadox Medicals, Div. Boston Scientific Corp.1996—
−9K962433Meadox Exxcel Eptfe Vascular GraftMeadox Medicals, Div. Boston Scientific Corp.1997—
−8K052964Exxcel and Exxcel Soft Eptfe Vascular Grafts, Microvel Double Velour Knitted…Boston Scientific Corp20063
−7K071778Hero Vascular Access DeviceGraftcath, Inc.2008—
−6K091491Hero Vascular Access DeviceHemosphere, Inc.2009—
−5K120006Hero GraftHemosphere, Inc.2012—
−4K121532Hero GraftHemosphere, Inc.2012—
−3K124039Hero GraftHemoshpere, Inc., A Cryolife Company2013—
−2K172637HeRO GraftMerit Medical Systems, Inc.2017—
−1K203724HeRO Graft, HeRO AdapterMerit Medical Systems, Inc.2021—
0 (this device)K213845HeRO GraftMerit Medical Systems, Inc.2022—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
198120
198220
198310
198410
198810
199410
199520
199710
200310
FIG. 1 — Lineage of K213845, 1979–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DSY? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new DSY device

  1. #1 K252445 Fusion Bioline Vascular Graftscore 12.4 · 5 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K203724HeRO Graft, HeRO Adapter
Summary page 4
…Classification Name: Prosthesis, Vascular Graft, of 6mm and Predicate Greater Diameter Device Premarket Notification: K203724 Manufacturer: Merit Medical Systems, Inc. This predicate has not been subject to a de…
Merit Medical Systems, Inc.2021—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 43 years and passes through 7 companies; a new generation was cleared every 2.1 years on median.
  • 1 of the 23 ancestors has a recall of any class.

How does its category compare?

All DSY devices

DSY Prosthesis, Vascular Graft, Of 6mm And Greater Diameter: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.

FDA decisions per year · DSY

2in 2025

2007: 12008: 12009: 52010: 42011: 12012: 42013: 52014: 22015: 12016: 12017: 32018: 12019: 12020: 12021: 22022: 22023: 22024: 52025: 22026 (partial year): 1
2007high 5 (2009) · low 1 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DSY

160in 2024

2009: 73 days median2010: 55 days median2012: 30 days median2013: 69 days median2017: 269 days median2024: 160 days median
2007high 269 (2017) · low 30 (2012)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · DSY

1in 2025

2009: 22010: 52013: 12016: 22025: 12026 (partial year): 1
2007high 5 (2010) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DSY

151in 2025

2007: 1202008: 1642009: 1932010: 1872011: 1652012: 1772013: 2072014: 3522015: 4602016: 2172017: 1932018: 2002019: 2322020: 1692021: 1682022: 1552023: 1492024: 1532025: 151
2007high 460 (2015) · low 120 (2007)2025

MAUDE reports naming product code DSY, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—0120
20081—0164
20095732193
20104555187
20111—0165
20124300177
20135691207
20142—0352
20151—0460
20161—2217
201732690193
20181—0200
20191—0232
20201—0169
20212—0168
20222—0155
20232—0149
202451600153
20252—1151
20261—1—

What is it indicated for?

The HeRO Graft is indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options. These catheter-dependent patients are readily identified using the KDOQI guidelines as patients who: • Have become catheter-dependent or who are approaching catheter-dependency (i.e., have exhausted all other access options, such as arteriovenous fistulas and grafts). • Are not candidates for upper extremity fistulas or grafts due…

Read the full statement (173 words)

The HeRO Graft is indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options. These catheter-dependent patients are readily identified using the KDOQI guidelines as patients who:

• Have become catheter-dependent or who are approaching catheter-dependency (i.e., have exhausted all other access options, such as arteriovenous fistulas and grafts).

• Are not candidates for upper extremity fistulas or grafts due to poor venous outflow as determined by a history of previous access failures or venography.

• Are failing fistulas or grafts due to poor venous outflow as determined by access failure or venography (e.g. fistula/graft salvage).

• Have poor remaining venous access sites for creation of a fistula or graft as determined by ultrasound or venography.

• Have a compromised central venous system or central venous stenosis (CVS) as determined by a history of previous access failures, symptomatic CVS (i.e., via arm, neck, or face swelling) or venography.

• Are receiving inadequate dialysis clearance (i.e., low Kt/V) via catheters. KDOQI guidelines recommend a minimum Kt/V of 1.4.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K213845: HeRO Graft.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K213845

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026